Karolinska Development AB

153 articles about Karolinska Development AB

• Karolinska Development's Portfolio Company Promimic Receives FDA Approval for HAnano Surface for Use on Dental Implants

  12/14/2017

  The approval of HAnano Surface in the United States has been executed in accordance with the new 510(k) legislation for medical devices.

• Karolinska Development Announces Outcome of the Extraordinary General Meeting

  11/28/2017

  The general meeting resolved to elect Miss Tse, Theresa as ordinary member of the board of directors until the end of the next Annual General Meeting.

• Karolinska Development Will Receive Shares in Pharmanest AB

  11/9/2017

  Karolinska Development AB today announces that the company will receive 140,149 shares in Pharmanest AB. Furthermore, the company will receive 11,527 shares via KCIF Co-Investment Fund.

• Karolinska Development Realizes Value Increase in the Portfolio Company Bioarctic Through a Partial Exit and Receives SEK 35 Million

  11/7/2017

  Karolinska Development today announces that the company has sold 1.5 million shares to a total amount of SEK 35 million in the portfolio company BioArctic Neurosciences AB in conjunction with the company being listed.

• Notice of EGM in Karolinska Development AB

  11/6/2017

  The shareholders of Karolinska Development AB are invited to the Extraordinary General Meeting on Tuesday November 28, 2017 at 16:00 (CET), at Tomtebodavagen 23 A in Solna, Sweden.

• Karolinska Development Publishes Interim Report (January - September 2017) and Reports A Positive Result for the Third Quarter

  10/31/2017

  The company will host a conference call and an online presentation on October 31, at 2 pm CET.

• Changes in the Board of Directors at Karolinska Development

  10/31/2017

  Dr Ewa Björling is a qualified dentist as well as a Medical Doctor and lecturer in virology.

• Change of Number of Shares and Votes in Karolinska Development

  10/31/2017

  Today, the last trading day of the month, there are 64,361,206, shares, representing a total of 77,889,088 votes outstanding in the Company, distributed among 1,503,098 shares of series A (with 15,030,980 votes) and 62,858,108 shares of series B (with 62,858,108 votes).

• Karolinska Development Divests Its Holdings in Xspray and Receives SEK 12.5 Million Directly and Additionally SEK 0.8 Million Via KCIF's Sale

  10/30/2017

  In September of 2015 Karolinska Development divested its holdings in Xspray to new owners.

• Karolinska Development - Interim Report (January-September 2017) - Invitation To Conference Call And Webcast

  10/27/2017

  The company will also host a conference call and an online presentation on October 31, at 2 pm CET.

• Karolinska Development's Portfolio Company Aprea Announces First Patient Enrolled In Clinical Phase Ib/II Study With APR-246 For The Treatment Of Esophageal Cancer

  10/16/2017

  Karolinska Development today announces that the portfolio company Aprea Therapeutics AB has enrolled the first patient in a Phase 1b/2 study with the drug candidate APR-246 for the treatment of esophageal cancer.

• Karolinska Development AB's Portfolio Company Umecrine Cognition Secures Financing For Clinical Development Of The Drug Candidate GR3027 Against Sleep Disorders

  10/4/2017

• Karolinska Development AB's Former Portfolio Company Xspray Pharma Is Listed On Nasdaq First North

  9/28/2017

• Karolinska Development AB's Portfolio Company Modus Recruits New Chief Medical Officer

  9/14/2017

• Karolinska Development AB's Portfolio Company Umecrine Cognition Presents Positive Phase Ib Data For Its Drug Candidate Against Hepatic Encephalopathy

  9/13/2017

• Karolinska Development AB's Portfolio Company BioArctic Intends To List On Nasdaq Stockholm

  9/13/2017

• Karolinska Development AB Umecrine Cognition Appoints Dr. Thomas P. Blackburn To Its Board Of Directors

  9/5/2017

• Change Of Number Of Shares And Votes In Karolinska Development AB

  8/31/2017

• Karolinska Development AB: Interim Report – January-June 2017

  8/29/2017

• Karolinska Development AB Appoints Fredrik Järrsten As Chief Financial Officer

  8/29/2017